Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole

Therapeutics and Clinical Risk Management

Volumn 8, Issue , 2012, Pages 359-366

  Corcia, Philippe ^a,b   Gordon, Paul H ^c  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Amyotrophic lateral sclerosis; Clinical trials; Dexpramipexole; Neurodegeneration; Survival

Indexed keywords

ARIMOCLOMOL; CEFTRIAXONE; CELECOXIB; DEXPRAMIPEXOLE; GABAPENTIN; GLATIRAMER; LITHIUM SALT; MEMANTINE; MINOCYCLINE; PLACEBO; RILUZOLE; TALAMPANEL; UBIDECARENONE; XALIPRODEN;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ASTHENIA; CELL LOSS; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; EXCITOTOXICITY; HUMAN; INFLAMMATION; MOTONEURON; NERVE CELL NECROSIS; NEUROPROTECTION; NEUTROPENIA; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN AGGREGATION; REVIEW; SURVIVAL; SYMPTOM; WEAKNESS;

EID: 84875308262     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S21981     Document Type: Review

References (79)

1. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the common neurologic disorders? Neurology. 2007;68:326-337.
2. Annegers JF, Appel S, Lee JR, Perkins P. Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985-1988. Arch Neurol. 1991;48:589-593.
3. Beghi E, Millul A, Micheli A, Vitelli E, Logroscino G. Incidence of ALS in Lombardy, Italy. Neurology. 2007;68:141-145.
4. Marin B, Gil J, Preux PM, Funalot B, Couratier P. Incidence of amyotrophic lateral sclerosis in the Limousin region of France, 1997-2007. Amyotroph Lateral Scler. 2009;10:216-220.
5. Alonso A, Logroscino G, Jick SS, Hernan MA. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol. 2009;16:745-751.
6. Chio A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology. 2009;72:725-731.
7. Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65:586-590.
8. Gordon PH, Delgadillo D, Piquard A, et al. The range and clinical impact of cognitive impairment in French patients with ALS: a cross-sectional study of neuropsychological test performance. Amyotroph Lateral Scler. 2011;12:372-378.
9. Blasco H, Guennoc AM, Veyrat-Durebex C, et al. Amyotrophic lateral sclerosis: A hormonal condition? Amyotroph Lateral Scler. 2012. [Epub ahead of print].
10. Gautier G, Verschueren A, Monnier A, Attarian S, Salort-Campana E, Pouget J. ALS with respiratory onset: clinical features and effects of non-invasive ventilation on the prognosis. Amyotroph Lateral Scler. 2010;11:379-382.
11. Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. 2009;73:805-811.
12. Logroscino G, Traynor BJ, Hardiman O, et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry. 2008;79:6-11.
13. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4:3.
14. Gordon PH, Corcia P, Lacomblez L, et al. Defining survival as an outcome measure in ALS. Arch Neurol. 2009;66:758-761.
15. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Amyotrophic lateral sclerosis mimic syndromes: a population based study. Arch Neurol. 2000;57:109-113.
16. Leigh PN, Abrahams S, Al-Chalabi A, et al. The management of motor neurone disease. J Neurol Neurosurg Psychiatry. 2003;74 Suppl 4:iv32-iv47.
17. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293-299.
18. De Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119:497-503.
19. Boekestein WA, Kleine BU, Hageman G, Schelhaas HJ, Zwarts MJ. Sensitivity and specificity of the 'Awaji' electrodiagnostic criteria for amyotrophic lateral sclerosis: retrospective comparison of the Awaji and revised El Escorial criteria for ALS. Amyotroph Lateral Scler. 2010;11:497-501.
20. Nelson LM, McGuire V, Longstreth WT Jr, Matkin C. Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. Am J Epidemiol. 2000;151:156-163.
21. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7:603-615.
22. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772-1775.
23. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344:1688-1700.
24. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65 Suppl 1:S3-S9.
25. Gordon PH, Meininger V: How can we improve clinical trials in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7:650-654.
26. Johri A, Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Ther. June 13, 2012. [Epub ahead of print.]
27. Menzies F, Ince PG, Shaw PJ. Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem Int. 2002;40:543-551.
28. Afifi AK, Aleu FP, Goodgold J, McKay B. Ultrastructure of atrophic muscle in amyotrophic lateral sclerosis. Neurology. 1966;16:475-481.
29. Bowling AC, Schulz JB, Brown HR Jr, Beal MF. Superoxide dismutase activity, oxidative damage and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem. 1993;61:2322-2325.
30. Cozzolino M, Ferri A, Valle C, Carri MT. Mitochondria and ALS: implications form novel gene and pathways. Mol Cell Neurosci. 2012. [Epub ahead of print].
31. Shi P, Gal J, Kwinter DM, Liu X, Zhu H. Mitochondrial dysfunction in amyotrophic lateral sclerosis. Biochim Biophys Acta. 2010;1892:45-51.
32. Cheah BC, Kiernan M. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. I Drugs. 2010;13:911-920.
33. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585-591.
34. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996; 347(9013):1425-1431.
35. Morren JA, Galvez-Jimenez N. Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis. Expert Opin Investig Drugs. 2012;21:297-320.
36. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;3:CD001447.
37. Rothstein JD. Therapeutic horizons for amyotrophic lateral sclerosis. Curr Opin Neurobiol. 1996;6:679-687.
38. Bozik M, Mather JL, Krammer WG, Gribkoff VK, Ingersholl EW. Safety, tolerability and pharmacokinetics of KNS-760704 (Dexpramipexole) in healthy adult subjects. J Clin Pharmacol. 2011;51:1177-1185.
39. Chio A, Bottacchi E, Buffa C, Mutani R, Mora G. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry. 2006;77:948-950.
40. Aboussouan LS, Khan SU, Banerjee M, Arroliga AC, Mitsumoto H. Objective measures of the efficacy of noninvasive positive-pressure ventilation in amyotrophic lateral sclerosis. Muscle Nerve. 2001;24:403-409.
41. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5:140-147.
42. Chio A, Finocchiaro E, Meineri P, Bottacchi E, Schiffer D. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. ALS Percutaneous Endoscopic Gastrostomy Study Group. Neurology. 1999;53:1123-1125.
43. Rowland LP Dr. Rowland's six levels of hope. ALSD33 ALS-On-Line. ALS Interest Group. ALS Digest #332. May 27, 1997.
44. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Northeast ALS Consortium. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003;61:456-464.
45. Miller RG, Moore DH, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. 2001;56:843-848.
46. Fornai F, Longone P, Cafaro L, et al, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2008;105:2052-2057.
47. Aggarwal SP, Zinman L, Simpson E, et al. Northeast and Canadian Amyotrophic Lateral Sclerosis consortia. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:481-488.
48. Chiò A, Borghero G, Calvo A, et al. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology. 2010;75:619-625.
49. Miller RG, Moore DH, Forshew DA, et al. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology. 2011;77:973-979.
50. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6:1045-1053.
51. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60:22-31.
52. Meininger V, Bensimon G, Bradley WR, et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Later Scler. 2004;5:107-117.
53. Meininger V, Drory VE, Leigh PN, Ludolph A, Robberecht W, Silani V. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler. 2009;10:378-383.
54. Ludolph AC, Bendotti C, Blaugrund E, et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler. 2010;11:38-45.
55. Cheung YK, Gordon PH, Levin B. Selecting promising ALS therapies in clinical trials. Neurology. 2006;67:1748-1751.
56. Gordon PH, Cheung YK, Levin B, et al. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler. 2008;9:212-222.
57. Levy G, Kaufmann P, Buchsbaum R, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology. 2006; 66:660-663.
58. Albrecht S, Buerger E. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole. Curr Med Res Opin. 2009;25:2977-2987.
59. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology. 1997;49:724-728.
60. Kushida CA. Pramipexole for the treatment of restless legs syndrome. Expert Opin Pharmacother. 2006;7:441-451.
61. Wahl F, Renou E, Mary V, Stutzmann JM. Riluzole reduces brain lesions and improves neurological function in rats after a traumatic brain injury. Brain Res. 1997;756:247-255.
62. Sethy VH, Wu H, Oostveen JA, Hall ED. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res. 1997;754:181-186.
63. Cassarino DS, Fall CP, Smith TS, Bennett JP Jr. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem. 1998;71:295-301.
64. Sayeed I, Parvez S, Winkler-Stuck K, et al. Patch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexole. FASEB J. 2006;20:556-558.
65. Izumi Y, Sawada H, Yamamoto N, Kume T, Katsuki H, Shimohama S, Akaike A. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Eur J Pharmacol. 2007;557:132-140.
66. Iravani MM, Sadeghian M, Leung CC, et al. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. Exp Neurol. 2008;212:522-531.
67. Hall ED, Andrus PK, Oostveen JA, Althaus JS, VonVoigtlander PF. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res. 1996;742:80-88.
68. Anderson DW, Neavin T, Smith JA, Schneider JS. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res. 2001;905:44-53.
69. Fujita Y, Izawa Y, Ali N, et al. Pramipexole protects against H2O2-induced PC12 cell death. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:257-266.
70. Pattee GL, Post GR, Bennett JP. Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:90-95.
71. Gribkoff FK, Bozik ME. KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. CNS Neurosci Ther. 2008;1:215-226.
72. Gu M, Iravani MM, Cooper JM, King D, Jenner P, Schapira AH. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem. 2004;91:1075-1081.
73. Ferrari-Toninelli G, Maccarinelli G, Uberti D, Buerger E, Memo M. Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole. BMC Pharmacol. 2010;10:2.
74. Abramova NA, Cassarino DS, Khan SM, Painter TW, Bennett JP Jr. Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J Neurosci Res. 2002;67:494-500.
75. Danzeisen R, Schwalenstoecker B, Gillardon F, et al. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther. 2006;316:189-199.
76. Frantz SW, Demady DR, Dalton JA, et al. Gottingen minipigs as the nonrodent species in the IND for KNS-760704. Int J Toxicol. 2010;29:1 Abs P17.
77. Alavian KN, Dworetzky SI, Bonanni L, et al. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetics efficiency. Brain Res. 2012;1446:1-11.
78. Wang H, Larriviere KS, Keller KE, et al. R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS. Amyotroph Lateral Scler. 2008;9:50-58.
79. Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011;17:1652-1657.